CO-DIAGNOSTICS INC (NASDAQ:CODX) Reports Q3 2025 Results, Missing Revenue Estimates

Co-Diagnostics Inc (NASDAQ:CODX) has released its financial results for the third quarter of 2025, presenting a mixed performance against analyst expectations. The market's immediate reaction, a decline in after-hours trading, suggests investors are weighing the reported figures against the company's ongoing operational narrative.

Q3 2025 Financial Results Versus Estimates

The company's performance for the quarter ended September 30, 2025, showed a slight beat on the bottom line but a significant miss on the top line. The key figures compared to Wall Street estimates are outlined below.

• Earnings Per Share (EPS): The company reported a non-GAAP loss per share of $0.16. This was marginally better than the analyst consensus estimate, which anticipated a loss of $0.1632 per share.
• Revenue: Co-Diagnostics posted revenue of $150,000 for the quarter. This fell substantially short of the $153,000 that analysts had projected, representing a notable miss on sales expectations.

Market Reaction and Recent Performance

The release of these figures was met with a negative response in the after-hours market, with the stock price declining over 4%. This immediate reaction indicates that investors may be more focused on the revenue shortfall than the modest earnings beat. This dip adds to a period of volatility for the stock, which has seen mixed performance over recent weeks.

• Last Month Performance: +6.26%
• Last Two Weeks Performance: -20.55%
• Last Week Performance: -5.61%

The sharp decline over the past two weeks, culminating in the post-earnings drop, points to a period of heightened investor uncertainty leading up to and following the earnings announcement.

Corporate Focus and Forward Outlook

According to the press release, Co-Diagnostics continues to emphasize its role as a molecular diagnostics company with a patented platform for developing diagnostic tests. The company's strategic focus remains on its Co-Dx PCR platform, which is designed for point-of-care and at-home use, aiming to automate and simplify complex molecular testing procedures. The announcement primarily served to report the quarterly financial results, and a specific financial outlook for the coming quarters was not detailed in the provided material. In the absence of company-provided guidance, investor attention will likely turn to how the company's trajectory aligns with existing analyst projections for the future.

Analyst Expectations for the Future

Wall Street has already established estimates for the company's upcoming performance, which will serve as a benchmark as Co-Diagnostics executes its strategy through the end of the fiscal year.

• Q4 2025 Estimates:
  • Estimated Revenue: $153,000
  • Estimated EPS: -$0.1275
• Full-Year 2025 Estimates:
  • Estimated Revenue: $523,260
  • Estimated EPS: -$0.7497

The company's ability to meet or exceed these estimates, particularly the revenue projection for the next quarter, will be a critical factor for investor sentiment moving forward.

For a more detailed breakdown of historical earnings and future analyst estimates, you can review the data here.

---

Disclaimer: This article is for informational purposes only and is not intended as investment advice. The information presented should not be construed as a recommendation to buy, sell, or hold any security. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions.